Cargando…

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

Botulinum toxin type A (BTA) injection is considered an available alternative treatment for myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome (MMPS) remains unclear. The purpose of this study was to evaluate whether the BTA injection into the affected muscles wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Montes-Carmona, Jose-Francisco, Gonzalez-Perez, Luis-Miguel, Infante-Cossio, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822413/
https://www.ncbi.nlm.nih.gov/pubmed/33374687
http://dx.doi.org/10.3390/toxins13010006
_version_ 1783639629817184256
author Montes-Carmona, Jose-Francisco
Gonzalez-Perez, Luis-Miguel
Infante-Cossio, Pedro
author_facet Montes-Carmona, Jose-Francisco
Gonzalez-Perez, Luis-Miguel
Infante-Cossio, Pedro
author_sort Montes-Carmona, Jose-Francisco
collection PubMed
description Botulinum toxin type A (BTA) injection is considered an available alternative treatment for myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome (MMPS) remains unclear. The purpose of this study was to evaluate whether the BTA injection into the affected muscles would significantly reduce pain and improve function, and to assess its efficacy, safety, and therapeutic indications in a randomized, single-center clinical trial. Sixty patients with MMPS were randomized into three groups evenly to receive a single session injection of saline solution (SS group), lidocaine (LD group), and BTA (BTA group) in the masseter, temporal, and pterygoid muscles after an electromyographic study. Patients’ pain was classified as localized or referred according to the DC/TMD classification. Assessments were performed on pre-treatment, and subsequently, on days 7, 14, 28, 60, 90, and 180. A significant reduction in pain and improvement of mandibular movements was found in the BTA group compared to the SS and LD groups. The response lasted until day 180 and was more intense in patients with localized myalgia and focused myofascial pain than in referred remote pain. No significant adverse reactions were observed. A single BTA injection can be considered an effective treatment option in patients with localized MMPS by reducing pain and improving mandibular movements, which persisted up to 6 months.
format Online
Article
Text
id pubmed-7822413
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78224132021-01-23 Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection Montes-Carmona, Jose-Francisco Gonzalez-Perez, Luis-Miguel Infante-Cossio, Pedro Toxins (Basel) Article Botulinum toxin type A (BTA) injection is considered an available alternative treatment for myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome (MMPS) remains unclear. The purpose of this study was to evaluate whether the BTA injection into the affected muscles would significantly reduce pain and improve function, and to assess its efficacy, safety, and therapeutic indications in a randomized, single-center clinical trial. Sixty patients with MMPS were randomized into three groups evenly to receive a single session injection of saline solution (SS group), lidocaine (LD group), and BTA (BTA group) in the masseter, temporal, and pterygoid muscles after an electromyographic study. Patients’ pain was classified as localized or referred according to the DC/TMD classification. Assessments were performed on pre-treatment, and subsequently, on days 7, 14, 28, 60, 90, and 180. A significant reduction in pain and improvement of mandibular movements was found in the BTA group compared to the SS and LD groups. The response lasted until day 180 and was more intense in patients with localized myalgia and focused myofascial pain than in referred remote pain. No significant adverse reactions were observed. A single BTA injection can be considered an effective treatment option in patients with localized MMPS by reducing pain and improving mandibular movements, which persisted up to 6 months. MDPI 2020-12-23 /pmc/articles/PMC7822413/ /pubmed/33374687 http://dx.doi.org/10.3390/toxins13010006 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Montes-Carmona, Jose-Francisco
Gonzalez-Perez, Luis-Miguel
Infante-Cossio, Pedro
Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title_full Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title_fullStr Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title_full_unstemmed Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title_short Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection
title_sort treatment of localized and referred masticatory myofascial pain with botulinum toxin injection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822413/
https://www.ncbi.nlm.nih.gov/pubmed/33374687
http://dx.doi.org/10.3390/toxins13010006
work_keys_str_mv AT montescarmonajosefrancisco treatmentoflocalizedandreferredmasticatorymyofascialpainwithbotulinumtoxininjection
AT gonzalezperezluismiguel treatmentoflocalizedandreferredmasticatorymyofascialpainwithbotulinumtoxininjection
AT infantecossiopedro treatmentoflocalizedandreferredmasticatorymyofascialpainwithbotulinumtoxininjection